Roth/MKM Downgrades Apellis Pharmaceuticals (APLS) to Neutral

April 2, 2026 3:04 AM

Roth/MKM analyst Adam Walsh downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Buy to Neutral with a price target of $41.00.The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found